The Oncology InstituteTOIIW 56 Receivables Turnover is 2.52 as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 657 Healthcare Providers & Services companies, The Oncology Institute ranks better than 60.88% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. The Oncology Institute's Revenue for the
three
months ended in Mar. 2026 was $147.44 Mil. The Oncology Institute's average Accounts Receivable for the
three
months ended in Mar. 2026 was $58.57 Mil.
Hence, The Oncology Institute's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.52.
The Oncology Institute (NAS:TOIIW) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
The Oncology Institute Receivables Turnover Related Terms
The Oncology Institute Receivables Turnover Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOIIW vs CYH, SRTA, CCRN: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOIIW) has a Receivables Turnover of 2.52 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #257 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 39.1%.
Is The Oncology Institute's Receivables Turnover too high?
The Oncology Institute's current Receivables Turnover is 2.52. The Healthcare Providers & Services industry median Receivables Turnover is 7.68. The Oncology Institute's value of 2.52 is 67.2% below this industry median. Based on the distribution chart, The Oncology Institute ranks #257 out of 657 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Receivables Turnover compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #257 out of 657 companies for Receivables Turnover. This puts The Oncology Institute in the upper half of its industry. The industry median Receivables Turnover is 7.68. The Oncology Institute's value of 2.52 is 67.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.68, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Oncology Institute's current Receivables Turnover of 2.52 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Receivables Turnover is 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Receivables Turnover of 2.52. The current Receivables Turnover is 2.52 and 67.2% below the Healthcare Providers & Services industry median of 7.68. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Receivables Turnover is 2.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
